Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two oncology conferences this month.
Galit Rotman, PhD, Chief Scientist of Therapeutics at Compugen, will deliver an oral presentation at the Immune Checkpoint Inhibitors conference to be held from March 24-26 in Boston. Dr. Rotman’s talk titled Novel Immune Checkpoints as Antibody Targets for Cancer Immunotherapy is part of a session named Validate Novel Pathways For Blockade Therapy. In her talk, Dr. Rotman will present experimental data demonstrating the immunomodulatory function of selected Compugen-discovered novel immune checkpoints as target candidates for cancer immunotherapy.
Help employers find you! Check out all the jobs and post your resume.
